Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinicopathologic characteristics of CCV-PTC and the paraneoplastic syndromes in follicular cell differentiated thyroid carcinoma were further summarized using literature review.
|
29446856 |
2018 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations between RET tagSNPs and their haplotypes and susceptibility, clinical severity, and thyroid function in patients with differentiated thyroid cancer.
|
29131865 |
2017 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CR = complete response; DM = distant metastases; DTC = differentiated thyroid cancer; ETE = extra-thyroidal extension; M0 = detected during follow-up; M1 = detected at diagnosis; MSKCC = Memorial Sloan Kettering Cancer Center; NED = no evidence of disease; OS = overall survival; PFS = progression free survival; PTC = papillary thyroid cancer; RAI = radioactive iodine; Tg = thyroglobulin.
|
28704099 |
2017 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of various somatic mutations in differentiated thyroid cancer was similar in Taiwan and Western countries, with the RAS kinase mutation and tyrosine receptor kinase (TRK) and rearranged during transfection (RET) proto-oncogenes being detected in lower frequencies and the B-type RAF kinase (BRAF) mutation accounting for the majority of cases.
|
25455162 |
2015 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results confirm that the FOXE1 rs965513 SNP confers an increased risk for DTC in the German population, particularly allele "A" and the genotypes "AA" and "AG" for PTC.
|
24325646 |
2014 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several diagnostic and prognostic molecular markers such as BRAF and RAS point mutations; RET/PTC and PAX8/PPARγ gene rearrangements; MAPK, PI3K, p53, Wnt-beta catenin, HIF1α and NF-kappaB signaling pathways; microRNA profiles and aberrant methylation have been demonstrated in more than 70% of DTC.
|
24405857 |
2014 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma.
|
24510380 |
2014 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this case-control study was to determine the effect of four well known RET single nucleotide polymorphisms (SNPs) on the risk for differentiated thyroid carcinoma.
|
25330015 |
2014 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.
|
23828865 |
2013 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
German patients (n=253) with DTC (papillary thyroid carcinoma [PTC] and follicular thyroid carcinoma [FTC]) and HC (n=302) were genotyped for polymorphisms within the vitamin D metabolizing enzymes such as 25-hydroxylase (CYP2R1[rs12794714, rs10741657]), 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1[rs10877012, rs4646536]), and 25-hydroxyvitamin D 24-hydrolase (CYP24A1[rs927650, rs2248137, rs2296241]).
|
22690899 |
2012 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic alterations in the mitogen-activated protein kinase pathway, including mutations of BRAF, RAS, and RET genes, have been implicated in the development of differentiated thyroid carcinoma arising in the thyroid gland.
|
19898969 |
2010 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genotype distributions were similar between DTC cases (n = 101) and controls (n = 174) except for RET 7 and RET 14 (P = .003 and P = .047, respectively) and between BTD cases (n = 62) and controls except for RET 14 (borderline; P = .064).
|
15933516 |
2005 |
Differentiated Thyroid Gland Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, chromosomal abnormalities are frequent in ATCs associated with FTC, but uncommon in those associated with PTC and in ATCs with no associated differentiated thyroid cancer.
|
12729478 |
2003 |